Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

The anti-CCR5 antibody PRO 140 has shown potent and prolonged antiretroviral activity in subjects infected with CCR5-tropic (R5) HIV-1. Prior studies have examined single intravenous doses ranging up to 5 mg/kg of body weight or up to three subcutaneous doses ranging up to 324 mg. Here we report the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jacobson, Jeffrey M., Lalezari, Jacob P., Thompson, Melanie A., Fichtenbaum, Carl J., Saag, Michael S., Zingman, Barry S., D'Ambrosio, Paul, Stambler, Nancy, Rotshteyn, Yakov, Marozsan, Andre J., Maddon, Paul J., Morris, Stephen A., Olson, William C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology (ASM) 2010
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2944554/
https://ncbi.nlm.nih.gov/pubmed/20660677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00086-10
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados